ASN95 -- Selected abstracts: Erythropoietin / Anemia

Sun. Nov. 5 1995

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Dialysis adequacy: Estimates and results

Program number 230 Board# S230 at 10:45 A.M.
* Underdialysis impairs response to erythropoietin in hemodialysis patients. O. Ifudu, J. Feldman and E.A. Friedman. - Brooklyn, NY.

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Clinical transplantation II

Program number 379 Board# S379 at 10:45 A.M.
* Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. J. Gossmann, P. Thurmann, T. Bachmann, S. Weller, H.-G. Kachel, W. Schoeppe and E.-H. Scheuermann. - Frankfurt am Main, Germany.

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Diabetes mellitus

Program number 447 Board# S447 at 10:45 A.M.
* Hyporeninemiais associated with erythropoietin deficiency in type I diabetic patients. S. Donnelly. - Toronto, Canada.

Program number 450 Board# S450 at 10:45 A.M.
* Erythropoietin delays the onset of uremia in anemic azotemic diabetic predialysis patients. C.D. Brown, Z.H. Zhao, L.L. Thomas and E.A. Friedman. - Brooklyn, NY.

9:30 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Myocytes/vascular smooth muscle cells

Program number 612 Board# S612 at 10:45 A.M.
* Gene expression in uremic left ventricular hypertrophy: Effects of hypertension and anemia. Y.K. Pak, A.Daraksharapu, S.L. Chang, P.S. Kim and R.H.K. Mak. - Stanford, CA.

4:00 P.M. ---Free Communications--- San Diego Conv Ctr Rm 8
Erythropoietin use and response in end-stage renal disease

Program number 672 at 4:00
* Correction of anemia does not improve growth or endocrinefunction in children with ESRD: A report from the U.S. multicenter pediatric recombinant erythropoietin study. C. Van dop, K.L. Jabs, S.A. Alexander, I.B. Salusky and D. McCabe. - Los Angeles and Thousand Oaks, Ca; Boston, MA and Dallas, TX.


Program number 673 at 4:15
* Effect of chronic human recombinant erythropoietin therapy on immune responses in chronic hemodialysis patients. L.A. Hebert, D.J. Birmingham, X.P. Shen, J.A. Hartman and J.J. Dillon. - Columbus, Oh.

Program number 674 at 4:30
* Interferon-gamma mediates resistance to erythropoietin in uremic patients with inflammatory disease. D.A. Allen, I.C. MacDougall and A.E.G. Raine. - London, United Kingdom.

Program number 675 at 4:45
* Cell therapy for erythropoietin deficient anemias. H.D. Humes, D.A. Cieslinski and A.J. Funke. - Ann Arbor, MI.

Program number 677 at 5:15
* Low iron absorption in erythropoietin-treated haemodialysis patients. M.P. Kooistra, A. Van es, A. Struyvenberg and J.J.M. Marx. - Utrecht and Hilversum, The Netherlands.

Program number 679 at 5:45
* Effect of normal versus anemic hematocrit on ambulatory blood pressure in erythropoietin-treated hemodialysis patients. J.S. Berns, M.R. Rudnick, R.M. Cohen and A. Maloney.- Philadelphia, PA.

Mon. Nov. 6 1995

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Health service research

Program number 839 Board# M108 at 10:00 A.M.
* Access to and utilization of ESRD-related services among state prisoner populations, 1989-1993. C. Feinberg, K.J. Fitzpatrick, M. Thamer and D. Cotter. - Washington, DC.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Complications and outcomes in end-stage renal disease I

Program number 863 Board# M132 at 10:00 A.M.
* Hemodialysis patients have increased susceptibility to complement c5b-9 mediated erythrocyte lysis and ghostformation. J. Himmelfarb, E. McMonagle and R. Hakim. - Portland, ME and Nashville, TN.

Program number 880 Board# M149 at 10:00 A.M.
* Can the erythropoietin dose be lowered safely? A case-control study of subcutaneous administration. K.P. Parker, T. LaCoursiere, E.J. Macon, J.C. Stivelman, J.L. Bailey, W.E. Mitch and J.M. Sands. - Atlanta,Ga.


Program number 881 Board# M150 at 10:00 A.M.
* Amelioration of anemia can regress the left ventricular hypertrophy in long-term hemodialysis patients. S. Haginoshita, S. Miyazaki, H.Yamazaki, Y. Koda, Y. Yuasa, S. Sakai, M. Suzuki, S. Takahashi, M. Tsutsui and Y. Hirasawa. - Niigata, Japan.

Program number 882 Board# M151 at 10:00 A.M.
* Changes in plasma endothelin concentration and hemodynamic parameters during recombinant human erythropoietin administration in maintenance hemodialysis patients. D.H. Kang, K.B. Choi, K.I. Yoon and D.S. Han. - Seoul, Korea.

Program number 883 Board# M152 at 10:00 A.M.
* O2 transport and cellular bioenergetics (P31-nmrs) after erythropoietin in chronic renal failure patients. J.M.Campistol, R.M. Marrades, J. Roca, J.V. Torregrosa, J. Alonso, J.M. Gonzalez de Suso, J.A. Barbera, O. Diaz, J.R. Masclans and R. Rodriguez-Roisin. - Barcelona, Spain.

Program number 884 Board# M153 at 10:00 A.M.
* Relationshipbetween o2 supply and o2 consumption after erythropoietin therapy in hemodialysis patients. J.M. Campistol,R. Marrades, J.V. Torregrosa, O. Diaz, J. Roca, J.A. Barbera and R. Rodriguez-Roisin. - Barcelona, Spain.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Nutrition and dialysis

Program number 1008 Board# M277 at 10:00 A.M.
* Role of endogenous erythropoietin in the hematopoietic response to iron administration in hemodialysis patients. S.R. Acchiardo, L.Moore, S.O. Smith, L.B. Burk, S.J. Smith and K. Will. - Memphis, TN.

Program number 1009 Board# M278 at 10:00 A.M.
* Comparison of 3 iron dextran infusion methods to correct anemia in erythropoietin treated hemodialysis patients. J.F. Winchester, M. McGinley, A. Wahab, F. Hall, J. Anderson, G. Breifel and M. Auerbach. - Washington, DC and Baltimore, MD.

Tue. Nov. 7 1995

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Hypertension: Basic

Program number 1515 Board# T65 at 10:00 A.M.
* Sustained systemic arterial hypertension after chronic exposure to hypobaric hypoxia. Z.Q. Wang and N.D. Vaziri. - Irvine, CA.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Hypertension: Clinical II

Program number 1520 Board# T70 at 10:00 A.M.
* Acute effect of recombinant human erythropoietin on blood pressure and vasoactive substances in chronic hemodialysis patients. M. Doumoto, A. Tojo, K. Kimura, K. Oka, S. Yagi and H. Matsuoka. - Tochigi and Tokyo, Japan.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Access methods of peritoneal dialysis

Program number 1618 Board# T168 at 10:00 A.M.
* Endogenous erythropoietin levels are elevated in patients on continuous ambulatory peritoneal dialysis. B.G. Delano, O. Ifudu, M. Joseph and E.A. Friedman. - Brooklyn, NY.

9:00 A.M. ---Poster--- San Diego Conv Ctr Halls A and B
Clinical and experimental peritoneal dialysis

Program number 1644 Board# T194 at 10:00 A.M.
* The safety and efficacy of intraperitoneal erythropoietin in children on CCPD. R.P. Valentini, A.B. Sedman, W.E. Smoyer, D. Kershaw, M. Gregory and T.E. Bunchman. - Ann Arbor, MI.

Wed. Nov. 8 1995

10:00 A.M. ---Free Communications--- San Diego Conv Ctr Rm 11a
Hypertension: Clinical

Program number 2193 at 11:00
* Endogenous erythropoietin correlates with arterial blood pressure in essential hypertension. M.R.W. Langenfeld, G. Rupprecht, H.P. Schobel and R.E. Schmieder. - Nuremberg, Germany.

Use BACK arrow on your browser (faster) or click here to go back to ASN95 main page

UP Click on ARROW for HDCN Home Page.